Page 24 - Delaware Medical Journal - March 2016

PUBLIC HEALTH
Coverage of Cessation Services
The Affordable Care Act has changed coverage for tobacco cessation, but we still have a long way to go in Delaware. Patients should understand that the State Medicaid program, the State Employee Health Plans, the health insurance marketplace plans, and many employer-sponsored plans offer varying coverage for tobacco cessation medication and counseling. Patients should be encouraged to check with their plans and employers to determine coverage.
CONCLUSION
With the increased focus on population health, this is an important time to more aggressively and appropriately treat our patients with CAD who use tobacco. Although physicians may have been hesitant to prescribe NRT for cardiac patients, there is a strong evidence base that NRT is safe to use in smokers with ACS. Clearly, any cardiovascular risks from cessation. Clinicians have a unique opportunity to both motivate tobacco users to quit and connect them to evidence-based treatment
REFERENCES
1. Gerber Y. Smoking status and long-term survival after first acute
myocardial infarction J Am Coll Cardiol. 2009;54;2382-2387.
2. Buchanan D. Association of smoking status with angina and health related quality of life after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015;8;1-8.
3. Critchley J. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease JAMA. 2003;290:86-97.
4. Moore R, ed. The physiological effects of nicotine. In: Tobacco in Australia: Facts and Issues. Vol 4th ed. Carlton,VIC: Cancer Council Victoria; 2012. Available at: http://www.tobaccoinaustralia.org.au/ chapter-6-addiction/6-2the-physiological-effects-of-nicotine.
5. Benowitz NL. Nicotine addiction. Prim Care. 1999;26(3):611-631.
6. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Nicotine Addiction: Past and Present. In: How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking- Attributable Disease: A Report of the Surgeon General. Vol Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK53018/. Accessed August 7, 2015.
7. Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130:e344-e426.
8. Fiore M, Jaen C, Baker T, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville MD: US Dept of Health and Human Services; May 2008.
9. Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005;95:976-978.
10. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol. 2012;110:968-970.
for tobacco cessation to maximize their success. The highest success rates result from the proven combination therapy of tobacco cessation medications and counseling.
CONTRIBUTING AUTHORS
■ DENISE TAYLOR, MS, RD is a Registered Dietitian and Project Manager of Million Hearts Delaware at Christiana Care Health System in Newark, Del.
■ ELISABETH BRADLEY, MS, APN is an Advanced Practice Nurse and the Clincial Leader of the Cardiovascular Prevention Program at Christiana Care Health System.
■ STEPHEN MENG, MD is a first year Cardiology Fellow at Christiana Care Health System.
■ JHAPAT THAPA, MD is a second year Fellow in Cardiovascular Disease at Christiana Care Health System.
■ EDWARD GOLDENBERG, MD is Medical Director of Cardiovascular Prevention at Christiana Care Health System and Chairman of Million Hearts Delaware.
11. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91-111.
12. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am J Heart. 2005;149:565-572.
13. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD000031. doi:10.1002/14651858.CD000031.pub3.
14. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946-955.
15. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and metaanalysis. Can Med Assoc J. 2011;183:1359-1366.
16. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. Br Med J. 2012;344:e2856.
17. FDA. Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events 2012 [June 2013]. Available online from: http://www.fda.gov/Drugs/DrugSafety/ ucm330367.htm
18.
19.
20.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221-229.
Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors.
Am Psychol.1992;47:1102-1114.
Centers for Disease Control and Prevention (CDC). Quitting smoking among adults: United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513-19.
88
Del Med J | March 2016 | Vol. 88 | No. 3